A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.

Press, Oliver W

A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Dec 2013 - 6624-32 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1557-3265

10.1158/1078-0432.CCR-13-1120 doi


Adult
Aged, 80 and over
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Murine-Derived--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Clinical Trials, Phase III as Topic
Cyclophosphamide--administration & dosage
Disease-Free Survival
Doxorubicin--administration & dosage
Hemoglobins--metabolism
Humans
Kaplan-Meier Estimate
Lymph Nodes--pathology
Lymphoma, Follicular--blood
Middle Aged
Multivariate Analysis
Organ Size
Prednisone--administration & dosage
Prognosis
Proportional Hazards Models
Rituximab
Vincristine--administration & dosage
Young Adult
beta 2-Microglobulin--blood